This retrospective cohort study of 559 surgically treated soft tissue sarcoma patients examines whether surgical margin quality independently predicts metastasis. Patients received surgery alone (no adjuvant therapy), allowing isolation of the surgical margin effect. The central question: does getting a bad margin — or the local recurrence that follows — actually cause metastatic spread?
For years, the observed correlation between local recurrence and metastasis in sarcoma led many to believe that aggressive local control — wider margins, more radiation — would improve survival. This paper challenges that directly.
When you see a soft tissue sarcoma patient postoperatively with a marginal or intralesional margin, counsel them that re-excision or radiation reduces the chance of local recurrence (RR 2.9 without adequate margin), but do not tell them their survival odds have changed because of the margin alone.
The factors that predict who dies are grade and size: high-grade tumors larger than 7 cm carry a 5-year metastasis-free survival of only 55%, regardless of margin status. Those are the patients who need systemic therapy discussions, not just local control optimization.
When a patient develops local recurrence, treat it as a biological signal — this tumor is behaving aggressively and the metastasis risk is now 4.4 times higher. That finding should prompt re-staging and reconsideration of adjuvant chemotherapy, not the assumption that the recurrence itself is what is killing the patient.
This retrospective cohort study of 559 surgically treated soft tissue sarcoma patients examines whether surgical margin quality independently predicts metastasis. Patients received surgery alone (no adjuvant therapy), allowing isolation of the surgical margin effect. The central question: does getting a bad margin — or the local recurrence that follows — actually cause metastatic spread?
For years, the observed correlation between local recurrence and metastasis in sarcoma led many to believe that aggressive local control — wider margins, more radiation — would improve survival. This paper challenges that directly.
When you see a soft tissue sarcoma patient postoperatively with a marginal or intralesional margin, counsel them that re-excision or radiation reduces the chance of local recurrence (RR 2.9 without adequate margin), but do not tell them their survival odds have changed because of the margin alone.
The factors that predict who dies are grade and size: high-grade tumors larger than 7 cm carry a 5-year metastasis-free survival of only 55%, regardless of margin status. Those are the patients who need systemic therapy discussions, not just local control optimization.
When a patient develops local recurrence, treat it as a biological signal — this tumor is behaving aggressively and the metastasis risk is now 4.4 times higher. That finding should prompt re-staging and reconsideration of adjuvant chemotherapy, not the assumption that the recurrence itself is what is killing the patient.